Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX)

Historical Holders from Q2 2018 to Q3 2025

Symbol: AMRX on Nasdaq
Type / Class: Equity / Class A Common Stock, par value $0.01
Shares outstanding: 315,976,000
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 149,537,932
Holdings value: $1,497,239,394
% of all portfolios: 0%
Number of holders: 243
Number of buys: 131
Number of sells: -103
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX)

Filer	Ownership	Change %	Holdings Value	Nb Shares	Change %	Reporting Name	Report Period
Patel Tushar Bhikhubhai	15.7%		$407,085,391	48,578,209		Patel Tushar Bhikhubhai	14 Mar 2025
Patel Chintu	8.2%		$259,359,420	25,910,032		Patel Chintu	03 Oct 2025
Patel Dipan	7.6%	-1.2%	$238,528,210	23,828,992	0%	Patel Dipan	03 Oct 2025
Patel Chirag K.	7.1%		$176,777,955	22,180,421		Patel Chirag K.	06 Aug 2025
Mahesh Akram	6.56%		$172,282,400	20,558,759		Akram Mahesh	31 Mar 2025
VANGUARD GROUP INC	5.02%		$132,091,652	15,762,727		The Vanguard Group	31 Mar 2025

Institutional Holders of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	149,537,932	$1,497,239,394	+$80,964,127	$0	$3,577,574	$10.01	243
2025 Q2	141,656,835	$1,146,033,099	+$54,531,165	$398,837	$1,572,696	$8.09	237
2025 Q1	134,446,153	$1,126,693,374	+$84,513,716	$860,626	$2,527,408	$8.38	231
2024 Q4	125,924,745	$997,304,941	-$136,419,334	$1,117,512	$2,867,040	$7.92	194
2024 Q3	142,604,810	$1,186,537,769	+$32,197,946	$407,680	$474,240	$8.32	180
2024 Q2	138,650,532	$880,442,706	+$192,209,856	$291,465	$1,487,805	$6.35	180
2024 Q1	108,100,412	$655,086,652	-$9,856,313	$496,314	$1,999,194	$6.06	173
2023 Q4	3,856,052	$23,416,321	-$574,329			$6.07	3
2023 Q3	101,896,343	$430,042,740	+$19,687,726	$7,596	$427,486	$4.22	141
2023 Q2	97,368,876	$301,754,108	+$4,217,184	$117,490	$308,450	$3.1	121
2023 Q1	96,404,763	$133,992,130	-$8,234,383	$27,661	$56,990	$1.39	139
2022 Q4	101,827,015	$202,640,136	+$4,431,021	$73,232	$95,520	$1.99	153
2022 Q3	91,936,831	$185,729,628	-$770,772	$174,000	$368,000	$2.02	139
2022 Q2	97,853,345	$311,192,849	-$2,007,306	$333,000	$456,000	$3.18	137
2022 Q1	92,598,580	$385,758,539	-$3,150,382	$1,348,000	$630,000	$4.17	151
2021 Q4	100,273,941	$478,793,810	-$1,213,873	$1,253,000	$1,185,000	$4.79	145
2021 Q3	100,314,917	$534,951,080	+$2,644,924	$2,192,000	$2,295,000	$5.34	150
2021 Q2	99,530,970	$509,505,477	-$13,562,876	$1,609,000	$1,368,000	$5.12	153
2021 Q1	101,561,492	$683,396,934	+$22,659,150	$1,749,000	$2,117,000	$6.73	154
2020 Q4	92,046,870	$420,590,386	-$4,897,752	$985,000	$1,539,000	$4.57	126
2020 Q3	93,114,553	$361,255,017	+$3,086,054	$453,000	$1,320,000	$3.88	129
2020 Q2	101,620,932	$483,700,077	+$13,664,961	$876,000	$1,679,000	$4.76	128
2020 Q1	98,243,413	$341,841,040	-$17,274,653	$470,000	$164,000	$3.48	114
2019 Q4	101,102,133	$487,286,241	-$9,238,952	$499,000	$2,000	$4.82	113
2019 Q3	108,233,131	$313,902,694	+$26,260,745	$585,000	$0	$2.9	108
2019 Q2	95,251,857	$682,942,286	-$98,037,351	$405,000	$658,000	$7.17	113
2019 Q1	101,633,429	$1,440,119,537	-$98,585,986	$184,000	$1,020,000	$14.17	143
2018 Q4	116,115,404	$1,571,109,084	+$90,619,744	$0	$1,588,000	$13.53	154
2018 Q3	107,940,783	$2,395,235,089	+$286,780,327	$235,000	$888,000	$22.19	159
2018 Q2	97,367,847	$1,597,817,365	+$1,597,526,989	$322,000		$16.41	159